Keywords
Treatment Resistance
Neprilysin Inhibitors
Renal Denervation
Polytherapy
How to Cite
Abstract
Arterial hypertension (AH) is a prevalent condition and one of the main causes of mortality and morbidity worldwide. Approximately 20% to 30% of hypertensive patients are unable to achieve adequate blood pressure control, even with the use of three or more medications, including diuretics, thus creating resistance to treatment. This study aims to comprehensively analyze the factors that contribute to this resistance, such as genetic predispositions, uncontrolled comorbidities, insufficient adherence to treatment and environmental variables. New therapeutic approaches are also discussed, such as the combination of neprilysin inhibitors and angiotensin II receptor antagonists, as well as interventions such as renal denervation and baroreceptor stimulation. Through a critical review of recent literature, this article offers a detailed overview of advances in the management of resistant hypertension and its clinical implications, proposing ways to optimize therapy and improve clinical outcomes.
References
Bakris, G. L. (2010). Managing resistant hypertension: past, present, and future. American Journal of Hypertension, 23(5), 487-496. Disponível em: https://academic.oup.com/ajh/article/23/5/487/4066114. Acesso em: 20 de julho de 2024
Burnier, M., Egan, B. M., & Oparil, S. (2019). Adherence to antihypertensive therapy and the management of blood pressure. Journal of the American College of Cardiology, 74(9), 1134-1140. Disponível em: https://www.jacc.org/doi/10.1016/j.jacc.2019.07.070
Calhoun, D. A., Jones, D., Textor, S., Goff, D. C., & Pimenta, E. (2008). Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association. Hypertension, 51(6), 1403-1419. Disponível em: https://www.ahajournals.org/doi/10.1161/HYP.0b013e318170c603. Acesso em 01 de Agosto de 2024
Fagard, R. H. (2012). Resistant hypertension: clinical implications and treatment perspectives. European Heart Journal, 33(5), 518-529. Disponível em: https://academic.oup.com/eurheartj/article/33/5/518/471728. Acesso em: 15 de Agosto de 2024
Gu, Q., Burt, V. L., Dillon, C. F., & Yoon, S. (2017). High blood pressure and cardiovascular disease morbidity and mortality. Cardiology Clinics, 35(3), 321-335. Disponível em: https://www.cardiology.theclinics.com/article/S0733-8651(17)30069-9/fulltext. Acesso em 15 de Agosto de 2024
Heusser, K., Tank, J., & Engeli, S. (2020). Baroreflex activation therapy for resistant hypertension. Journal of Hypertension, 38(9), 1757-1765. Disponível em: https://journals.lww.com/jhypertension/Fulltext/2020/09000/Baroreflex_activation_therapy_for_resistant.2.aspx. Acesso em 17 de Agosto de 2024
Kandzari, D. E., Bhatt, D. L., & Brar, S. (2018). Renal denervation for hypertension and beyond. JACC: Cardiovascular Interventions, 11(6), 533-543. Disponível em: https://www.jacc.org/doi/10.1016/j.jcin.2018.02.003. Acesos em 17 de Agosto de 2024
McMurray, J. J., Packer, M., Desai, A. S., & Gong, J. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa1409077. Acesso em 17 de Agosto de 2024
Sociedade Brasileira de Cardiologia. (2020). Diretrizes Brasileiras de Hipertensão Arterial. Arquivos Brasileiros de Cardiologia, 114(2), 257-342. Disponível em: https://www.scielo.br/j/abc/a/JbhKLwr8YwtcckmF8ZJ8Rnj/?lang=pt. Acesso em: 18 de Agosto de 2024.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Gabriel Leonardo de Andrade Neto, Luiza Aguiar Puff, Eduardo Nogueira Botinha , Maria Clara Leal Ferreira